NeoVirTech - Antiviral screening & discovery

Imaging for the discovery of tomorrow's antivirals

Virus infection and replication in living cells

Measurement of disinfection efficiency

ANCHOR^TM
Breakthrough tehnology

Next generation technology for virus/viral vector imaging applied in antiviral screening, gene delivery, oncolytic virotherapies and the measurement of disinfection processes

Virology

NeoVirTech has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells. Application in antiviral discovery and disinfection procedures

Oncolytic virotherapies

Conventional cancer treatments have limited effectiveness in many cases. Oncolytic therapy, based on the use of armed viruses directed against tumor cells, offers new perspectives in the fight against this global scourge.

Drug discovery

Using autofluorescent viruses, we can measure the impact of the presence of a molecule of interest on virus infection and replication capacities.

Disinfection testing

Our technology allows us to quickly calibrate and validate the development of disinfection devices

Imaging

We can offer different types of imaging and also image analysis whether in a viral or non-viral context, from high content imaging to high resolution imaging and light sheet microscopy.

News

Press release

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech’s autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing.

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech's autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing. What if we...

Press release

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market NeoVirTech (NVT) and BioImmunitas Ltd enter...

Picture

Picture of the month, January 2023

Picture of the month, January 2023 Picture (art) of the month, January 2023. Human cells infected with VACV ANCHOR poxvirus (green: infected cells, greendots:...

Press release

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech’s autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing.

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech's autofluorescent viruses with VirexpR nebulization technologies for airborne...

Press release

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market NeoVirTech...

Assets

Patents

Viruses available

Worldwide customers

3000

Million parameters measured

BSL2 & BSL3 Lab

Performing the best virology services in BSLII and BSLIII environnement

A word from Franck, our CEO

Having the ability to directly visualize virus infection and replication in living cells using a breakthrough technology with minimum hands-on investment. This is what we propose at NeoVirTech. Our state of the art imaging and screening platform provides a rapid and powerful pipeline to discover compounds that will impact infection capacities and measure disinfection procedures on a large collection of viruses in the human and veterinary market. As our technology is image-based, the beauty and quality of the data generated is a tremendous asset to boost your research and expand your communication processes.